Trials / Completed
CompletedNCT03990376
Adolescent Idiopathic Scoliosis (AIS) Gold Standard for Blood Loss
Establishment of a Gold Standard Formula for Blood Loss Calculation in Adolescent Idiopathic Scoliosis (AIS) Surgery
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Emory University · Academic / Other
- Sex
- All
- Age
- 10 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to establish a benchmark for measuring blood loss by directly measuring the change in red cell volume before and after surgery and to compare established blood loss estimators to this benchmark in order to determine the most accurate and precise method for estimating blood loss in adolescent idiopathic scoliosis surgery patients
Detailed description
Bleeding is a necessary and unavoidable part of spine surgery. It is important to the surgeons and anesthesiologists to know how much blood a patient has lost during surgery in order to care for them in the best way possible. Different methodology has been employed to estimate how much blood is lost during surgery, but unfortunately none of the methods used have been reliable. The study will calculate surgical blood loss by determining perioperative change in red cell volume that is directly measured by using a special method that relies on radioisotope I-131-labeled albumin administration (BVA-100) during the surgery. This benchmarked blood loss estimate will then be compared to estimates calculated using the Gross equation, the Bourke and Smith equation, and the Camarasa formula. In addition, blood loss will be estimated volumetrically by utilizing formulas based on the amount of salvaged blood produced by an intraoperative salvaging system (Cell Saver®). Blood loss estimates based on salvaged blood volume will also be compared to the benchmark.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Radioisotope I-131-labeled albumin | 1 mL of radioisotope I-131-labeled albumin x 2 |
Timeline
- Start date
- 2019-06-19
- Primary completion
- 2020-09-10
- Completion
- 2020-09-10
- First posted
- 2019-06-19
- Last updated
- 2021-06-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03990376. Inclusion in this directory is not an endorsement.